Clinical study of unrelated umbilical cord blood transplantation in 32 children patients.
- Author:
Xi-Feng JIANG
1
;
Bai-Jun SHENG
Author Information
1. Shandong Umbilical Cord Blood Bank, Jinan 250002, China. jiangxf@sinocord.com
- Publication Type:Journal Article
- MeSH:
Adolescent;
Antineoplastic Combined Chemotherapy Protocols;
therapeutic use;
Child;
Child, Preschool;
Cord Blood Stem Cell Transplantation;
methods;
Cyclosporine;
administration & dosage;
Graft vs Host Disease;
prevention & control;
Hematologic Neoplasms;
mortality;
therapy;
Humans;
Methotrexate;
administration & dosage;
Survival Rate;
Transplantation Conditioning
- From:
Journal of Experimental Hematology
2006;14(4):829-831
- CountryChina
- Language:Chinese
-
Abstract:
To evaluate the clinical efficacy of unrelated umbilical cord blood transplantation (UCBT) on the treatment of children with hematologic malignancies and nonmalignancies, between August 2001 and June 2004, 32 patients were transplanted by using unrelated umbilical cord blood supplied by Shandong Umbilical Cord Blood Bank. Out of them, 13 patients suffered from ALL, 9 from AML, 3 from AA, 3 from HAL, 2 from CML and 2 from NHL. The median age was 8 years (range 2-15), the median weight was 31.5 kg (range 14-55). All patients received ablative conditioning regiment according to the disease and the disease status. Conditioning regiments Cy/TBI were used for 4 patients and Bu/Cy for 21 patients, other for 7 patients. All patients received cyclosporin A and/or methotrexate for GVHD prophylaxis. The mean number of infused nuclear cells were 5.57 (2.16-12.3) x 10(7)/kg, CD34+ cells 1.78 (0.85-5.59) x 10(5). All of UCB units were tested for HLA-A, -B, and DRB1 using low and high resolution techniques. There were HLA-matched in 10, 5/6 in 16 and 4/6 in 6. The results showed that 20 out of 32 patients achieved complete engraftment. Median time of neutrophil > or = 0.5 x 10(9)/L, and platelet > or = 20 x 10(9)/L were 17 (9-38) and 42 (18-102) days respectively. The incidence of aGVHD II-IV and aGVHD III-IV were 35% and 15% respectively. After a median follow-up of 18 months (1.5-28.5), overall survival rate at one year was 59.4%, overall survival rate at two years was 40.6%. It is suggested that UCBT is promising for children patients who is lack of matched bone marrow donors.
